LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.29 USD | -1.42% |
|
-2.61% | -.--% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 6.73M | Capitalization | 390M |
|---|---|---|---|---|---|
| Net income 2024 * | -52M | Net income 2025 * | -66M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 58.1 x |
| P/E ratio 2024 * |
-5.46
x | P/E ratio 2025 * |
-6.38
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.17% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.42% | ||
| 1 week | -2.61% | ||
| 1 month | -3.65% |
1 week
15.11
16.01
1 month
15.0019.92
Current year
15.0024.59
1 year
15.0024.59
3 years
15.0024.59
5 years
15.0024.59
10 years
15.0024.59
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 15.29 | -1.42% | 123,978 |
| 24-05-30 | 15.51 | +0.13% | 151,624 |
| 24-05-29 | 15.49 | +0.65% | 252,140 |
| 24-05-28 | 15.39 | -1.97% | 155,392 |
| 24-05-24 | 15.7 | -0.13% | 214,482 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.29
USD
Average target price
35.6
USD
Spread / Average Target
+132.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 390M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- LENZ Stock
